Cost-Effectiveness of Cemiplimab Versus Standard of Care in the United States for First-Line Treatment of Advanced Non-small Cell Lung Cancer With Programmed Death-Ligand 1 Expression ≥50%
Titel:
Cost-Effectiveness of Cemiplimab Versus Standard of Care in the United States for First-Line Treatment of Advanced Non-small Cell Lung Cancer With Programmed Death-Ligand 1 Expression ≥50%
Auteur:
Kuznik, Andreas Smare, Caitlin Chen, Chieh-I Venkatachalam, Meena Keeping, Sam Atsou, Kokuvi Xu, Yingxin Wilson, Florence Guyot, Patricia Chan, Keith Glowienka, Emily Konidaris, Gerasimos
Verschenen in:
Value in health
Paginering:
Jaargang 25 () nr. 2 pagina's 203-214
Jaar:
2022
Inhoud:
Uitgever:
ISPOR–The International Society for Pharmacoeconomics and Outcomes Research, Inc